Evidence map›Paper›PMID 37090707›Full record

ArticleFrontiers in immunology2023

Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles.

Martina Borghi, Alessandra Gallinaro, Maria Franca Pirillo, Andrea Canitano, Zuleika Michelini, Maria Laura De Angelis, Serena Cecchetti, Antonella Tinari, Chiara Falce, Sabrina Mariotti and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Molecular therapy. Nucleic acids · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Martina BorghiDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Alessandra GallinaroNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Maria Franca PirilloNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Andrea CanitanoNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Zuleika MicheliniNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Maria Laura De AngelisDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Serena CecchettiConfocal Microscopy Unit, Core Facilities, Istituto Superiore di Sanità, Rome, Italy.
Antonella TinariCenter for Gender Medicine, Istituto Superiore di Sanità, Rome, Italy.
Chiara FalceNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Sabrina MariottiDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Antonio CapocefaloDepartment of Veterinary Public Health & Food Safety, Istituto Superiore di Sanità, Rome, Italy.
Maria Vincenza ChiantoreDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Angelo IacobinoDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Antonio Di VirgilioCenter for Animal Research and Welfare, Istituto Superiore di Sanità, Rome, Italy.
Marit J van GilsDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
Rogier W SandersDepartment of Medical Microbiology and Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
Alessandra Lo PrestiDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Roberto NisiniDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Donatella NegriDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Andrea CaraNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Istituto Superiore di Sanità · ITAmsterdam University Medical Centers · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several COVID-19 vaccine strategies utilizing new formulations for the induction of neutralizing antibodies (nAbs) and T cell immunity are still under evaluation in preclinical and clinical studies. Here we used Simian Immunodeficiency Virus (SIV)-based integrase defective lentiviral vector (IDLV) delivering different conformations of membrane-tethered Spike protein in the mouse immunogenicity model, with the aim of inducing persistent nAbs against multiple SARS-CoV-2 variants of concern (VoC). Spike modifications included prefusion-stabilizing double proline (2P) substitutions, mutations at the furin cleavage site (FCS), D614G mutation and truncation of the cytoplasmic tail (delta21) of ancestral and Beta (B.1.351) Spike, the latter mutation to markedly improve IDLV membrane-tethering. BALB/c mice were injected once with IDLV delivering the different forms of Spike or the recombinant trimeric Spike protein with 2P substitutions and FCS mutations in association with a squalene-based adjuvant. Anti-receptor binding domain (RBD) binding Abs, nAbs and T cell responses were detected up to six months from a single immunization with escalating doses of vaccines in all mice, but with different levels and kinetics. Results indicated that IDLV delivering the Spike protein with all the combined modifications, outperformed the other candidates in terms of T cell immunity and level of both binding Abs and nAbs soon after the single immunization and persistence over time, showing the best capacity to neutralize all formerly circulating VoC Alpha, Beta, Gamma and Delta. Although present, the lowest response was detected against Omicron variants (BA.1, BA.2 and BA.4/5), suggesting that the magnitude of immune evasion may be related to the higher genetic distance of Omicron as indicated by increased number of amino acid substitutions in Spike acquired during virus evolution.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingCOVID-19 VaccinesDisease Models, AnimalHumansImmunityIntegrasesMiceMice, Inbred BALB CSARS-CoV-2Antibodies, NeutralizingCOVID-19 VaccinesIntegrasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2IDLVlentiviral vector (LV)neutralizing AbsSARS-CoV-2vaccine

Identifiers

PMID37090707
PMCPMC10113491
OpenAlexW4362625960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.